PLYMOUTH
MEETING, Pa., Aug. 29,
2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a
biotechnology company focused on developing and commercializing DNA
medicines to help treat and protect people from HPV-related
diseases, cancer, and infectious diseases, today announced
that Dr. Jacqueline Shea, President
and CEO will present at the H.C. Wainwright 25th Annual Global
Investment Conference.
H.C. Wainwright 25th Annual Global Investment
Conference
Date: Tuesday, September
12, 2023
Time: 4:30 PM ET
Format: Company Presentation
During the conference, Dr. Shea and members of INOVIO's
management team will conduct one-on-one meetings with registered
investors.
A webcast of the presentation will be available on the INOVIO
Investor Relations Events page at
https://ir.inovio.com/events-and-presentations/default.aspx. A
replay of the webcast will be available for 90 days after the date
of the presentation.
About INOVIO
INOVIO is a biotechnology company focused on developing and
commercializing DNA medicines to help treat and protect people from
HPV-related diseases, cancer, and infectious diseases. INOVIO's DNA
medicines in development are delivered using its investigational
proprietary device, CELLECTRA®, to produce immune responses against
targeted pathogens and cancers. For more information, visit
www.inovio.com.
Contacts
Media: Jennie Willson (267)
429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267)
440-4298 thomas.hong@inovio.com
View original
content:https://www.prnewswire.com/news-releases/inovio-to-present-at-the-hc-wainwright-25th-annual-global-investment-conference-301911827.html
SOURCE INOVIO Pharmaceuticals, Inc.